An Unusual Cluster of Neuroinvasive Lyme Disease Cases Presenting With Bannwarth Syndrome in the Midwest United States

Aditya Shah, John C. O’Horo, John W. Wilson, Dane Granger, and Elitza S. Theel

1Division of Infectious Diseases and 2Division of Pulmonary and Critical Care, Department of Medicine, and Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota

Bannwarth syndrome (BWS), an infrequent manifestation of neuroinvasive Lyme disease (LD) characterized by radiculopathy, neuropathy, and lymphocytic pleocytosis, is more commonly documented in Europe than North America. Here, we describe a cluster of 5 neuroinvasive LD cases with BWS in the upper Midwest United States between July and August 2017.

**Keywords.** Lyme disease; neuroborreliosis; Bannwarth syndrome; neuroinvasive; Garin-Bujadoux-Bannwarth syndrome.

Garin-Bujadoux-Bannwarth syndrome (Bannwarth syndrome [BWS]) is an uncommon manifestation of neuroinvasive Lyme disease (LD) caused by infection with members of *Borrelia burgdorferi* sensu lato (Bbsl) complex and is more frequently described in patients with Lyme disease in Europe as compared with the United States [1]. BWS is characterized by painful radiculopathy, neuropathy, varying degrees of motor weakness and facial nerve palsy, and cerebrospinal fluid (CSF) lymphocytic pleocytosis.

Over 3 weeks between July and August 2017, Mayo Clinic campuses in Minnesota and Wisconsin identified 6 patients from the upper Midwest with Lyme neuroborreliosis (LNB), 5 presenting with BWS. Here, we present the findings of these 5 patients.

**CASES**

**Patient 1**
A 61-year-old male with daily tick exposure presented with progressive back pain, upper torso and extremity paresthesias, right-sided facial droop, and blurry vision in the right eye. Four weeks prior, the patient observed an erythema migrans (EM) rash, treated with 5 days of twice-daily doxycycline. CSF and serum were submitted for LD serologic testing using the standard 2-tiered testing algorithm and interpretive criteria (applied to serum) [2]. LD antibody index (AI), comparing the level of anti-Bbsl IgG in CSF and serum for determination of pathogen-specific IgG intrathecal antibody synthesis, was also performed [3]. LD IgM immunoblot was positive in serum, IgM and IgG antibodies to *B. burgdorferi* sensu stricto (*B. burgdorferi*) were detected in CSF, and LD AI was elevated at 5.28 (reference range, 0.6–1.29), which, alongside CSF lymphocytic pleocytosis (77 white blood cells [WBCs], 86% lymphocytes), led to a diagnosis of LNB/BWS (Table 1). The patient demonstrated significant neurologic improvement following 4 weeks of intravenous (IV) ceftriaxone.

**Patient 2**
A 62-year-old female presented with subacute onset of lower extremity weakness, progressing to flaccid paralysis over a 3-week period, alongside radiating low back and abdominal pain with associated numbness. A magnetic resonance image (MRI) of her spine showed diffuse inflammation of the cauda equina. CSF analysis was remarkable for lymphocytic pleocytosis (363 WBCs, 74% lymphocytes), elevated protein (649 mg/dL), and a high LD AI of 40.2. A *Borrelia* spp. real-time polymerase chain reaction (RT-PCR) assay was positive for *B. burgdorferi* in CSF (Table 1) [4]. The patient was diagnosed with LNB/BWS and discharged on a 4-week course of IV ceftriaxone. The patient reported improved mobility, though she still required extensive assistance 2 months post-treatment.

**Patient 3**
A 65-year-old female presented with subacute progressive ascending weakness and lower extremity paresthesias. Brain and spine MRI imaging were negative; however, CSF evaluation demonstrated lymphocytic pleocytosis (46 WBCs, 92% lymphocytes), elevated protein (113 mg/dL), and an LD AI of 2.49. The patient was positive for IgM and IgG antibodies to *B. burgdorferi* in serum, with both antibody classes also detected in CSF (Table 1). The patient was diagnosed with LNB/BWS and initiated on a 4-week course of IV ceftriaxone, and she reported significant improvement 2 weeks later.

**Patient 4**
A 29-year-old male developed fever, myalgias, chills, headache, fatigue, and a transient erythematous rash on his trunk in mid-June 2017. Two weeks thereafter, he developed right foot drop, Trendeleberg gait, lower extremity radiculopathy, and painful L5-S1 paresthesias. Over a 10-week period, he experienced constitutional symptoms, including a 15-pound weight loss. MRI of...
the lumbar spine showed nonspecific enhancement of the cauda equina roots. The patient was seropositive for both IgM and IgG to *B. burgdorferi*; an LP was refused (Table 1). Based on clinical presentation, imaging studies, and seropositivity to *B. burgdorferi*, the patient was diagnosed with LNB/BWS and initiated on IV ceftriaxone. At a 2-week follow-up, the patient indicated complete resolution of symptoms.

**Patient 5**

A 69-year-old male presented with low-grade fevers, nausea, vomiting, diffuse arthralgias, headache, loss of smell, and blurry vision in the right eye. These symptoms were accompanied by neck and right upper extremity pain in a radicular pattern. The patient was seropositive for IgM and IgG antibodies to *B. burgdorferi* in serum, with both immunoglobulin classes also detected in CSF, which showed a lymphocytic pleocytosis (142 WBCs, 88% lymphocytes) (Table 1). An LD AI was not performed due to limited specimen volume. The patient's constellation of symptoms, alongside CSF findings, led to a diagnosis of LNB/BWS, and IV ceftriaxone was initiated. Following completion of treatment, the patient reported complete resolution of all symptoms.

**DISCUSSION**

LD is predominantly caused by 3 members of the *B. burgdorferi* sl complex: *B. burgdorferi* is responsible for the majority of cases in North America, whereas *B. afzelii* and *B. garinii* are predominant in Europe and Asia [5, 6]. Approximately 300,000 cases of LD are estimated annually in the United States [7]. LD can involve numerous organ systems, including the central nervous system (CNS), the peripheral nervous system (PNS), or both, with approximately 10% of untreated patients developing PNS involvement [5, 8]. While the clinical manifestations of LNB vary, the triad of painful radiculopathy, cranial neuropathy, and lymphocytic pleocytosis, often occurring in early-onset neuroinvasive LD, are encompassed by BWS [9]. Additionally, patients with LNB and BWS often experience paresis and show enhancement of the spinal nerve roots in the lower spinal cord and/or cauda equina on imaging [10]. While the precise incidence of BWS in the United States is unknown, literature suggests that LNB associated with BWS is more frequent in Europe, where it is primarily associated with *B. garinii* infections [1, 10].

In this brief communication, we report that among 6 patients with LNB identified over a 3-week period in 2017, 5 presented with PNS involvement (primarily axonal in nature) consistent with BWS. This is an unexpectedly high incidence at our facility as compared with prior years, in which 1 or 2 cases of LNB with BWS are typically suspected annually.

All 5 patients presented with symptoms including upper or lower extremity radiculopathy and/or paresthesias. Typically, BWS is associated with limited radicular pain, as observed for 2 patients presented here. The more widespread peripheral neuropathy observed for the remaining 3 patients in this series is
somewhat atypical. Additionally, 2 patients developed visual disturbances and nerve root enhancement in the cauda equina or lumbar spine, and 1 presented with Lyme disease-associated facial nerve palsy. Four patients underwent CSF collection showing significant lymphocytic pleocytosis and high protein, consistent with BWS. The absence of CSF evaluation for patient 4 is a limitation for definitive LNB classification, although his presentation with improvement following treatment strongly supports the presence of neuroinvasive disease. Importantly, 4 out of 5 patients showed rapid response to antimicrobials, as expected with LNB. For the fifth patient, although symptomatic improvement was noted, the prolonged symptoms may be a result of a concomitant neurologic process, though an alternative explanation has not yet been identified.

While definitive laboratory diagnostic criteria have been well-established for non-neuroinvasive LD, diagnostic testing guidelines are not as well defined for confirmation of LNB in the United States. Detection of IgM and/or IgG class antibodies to *B. burgdorferi* by immunoblot in CSF is often performed, although there are no specific criteria established for interpretation of banding patterns in CSF. Also, due to the possibility of passive immunoglobulin diffusion across the blood-CSF barrier or the presence of serum antibodies in CSF as a result of a traumatic lumbar puncture, detection of antibodies to *Bbsl* in CSF does not solely confirm intrathecal synthesis [8]. Antibody synthesis by immunoblot in CSF is often performed, although there are no specific criteria established for interpretation of banding patterns in CSF. Also, due to the possibility of passive immunoglobulin diffusion across the blood-CSF barrier, the presence of serum antibodies in CSF as a result of a traumatic lumbar puncture, detection of antibodies to *Bbsl* in CSF does not solely confirm intrathecal synthesis [8]. Antibody synthesis can be established by determining a pathogen-specific IgG AI. The AI is a ratio of the level of pathogen-specific IgG antibodies in CSF:serum following normalization for total IgG in both specimen sources. An AI ratio of ≥1.5 is considered indicative of true, pathogen-specific intrathecal antibody synthesis [3]. The diagnostic sensitivity of the LD AI is variable (range, 55%–100%), largely dependent on the duration of symptoms prior to specimen collection [11]. Importantly, although offered through a limited number of reference laboratories in the United States, determining an LD AI is included in diagnostic and management guidelines for neuroinvasive LD from both the Infectious Diseases Society of America and the European Federation of Neurological Societies [6, 11]. In this case series, all 3 patients with sufficient CSF for LD AI testing were positive, with AI ratios ranging from 2.49 to 40.2. Finally, while definitive evidence of neuroinvasive LD includes detection of *Bbsl* nucleic acid in CSF, only 1 patient with LNB/BWS was RT-PCR positive in this series. This is consistent with previous studies showing that the sensitivity of RT-PCR in CSF for *Bbsl* is low, with a median sensitivity of 22.5% [12].

**CONCLUSIONS**

We report 5 cases of LNB with BWS in the upper Midwest United States. While this suggests an increased incidence of this presentation in our region, BWS associated with LD is not currently a reportable disease, and comparison with prior years is not possible. It remains prudent, however, for clinicians to be aware of this infrequent and possibly increasing clinical manifestation of LNB in the United States. The constellation of neurologic symptoms, particularly when associated with a recent or suspected tick bite in an LD-endemic region, should prompt clinical evaluation for LNB and assessment for BWS as this syndrome may be more common than previously presumed in North America.

**Acknowledgments**

Potential conflicts of interest. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Murray TS, Shapiro ED. Lyme disease. Clin Lab Med 2010; 30:311–28.
2. CDC. Notice to readers: recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR 1995; 44:590–1.
3. Reiber H, Lange F. Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain. Clin Chem 1991; 37:1153–60.
4. Babady NE, Sloan LM, Vetter EA, et al. Percent positive rate of Lyme real-time polymerase chain reaction in blood, cerebrospinal fluid, synovial fluid, and tissue. Diagn Microbiol Infect Dis 2008; 62:464–6.
5. Stanek G, Wormser GP, Gray J, Stiefe L. Lyme borreliosis. Lancet 2012; 379:461–73.
6. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089–134.
7. Hinckley AF, Connally NP, Meek JL, et al. Lyme disease: definition and laboratory evaluation for Lyme disease. MMWR 2014; 59:676–81.
8. Halperin JJ. Nervous system Lyme disease. Clin Lab Med 2015; 35:779–95.
9. Ogrinc K, Lanka L, Lotrič-Furlan S, et al. Course and outcome of early European Lyme neuroborreliosis (Bannwarth Syndrome): clinical and laboratory findings. Clin Infect Dis 2016; 63:346–53.
10. Hildenbrand P, Craven DE, Jones R, Nemeskal P. Lyme neuroborreliosis: manifestations of a rapidly emerging zoonosis. AJNR Am J Neuroradiol 2009; 30:1079–87.
11. Mygland A, Ljostad U, Fingerle V, et al. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 2010; 17:16–16, e1–34.
12. Rušič-Sabljić E, Cerar T. Progress in the molecular diagnosis of Lyme disease. Expert Rev Med Diagn 2017; 17:19–30.